SCHEMBL1925551

SCHEMBL1925551

CCCCCc1c[nH]c(CCCCC)c1CCCCC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 2/20 0.37
HTR1A P08908 1/20 0.36
HTR1D P28221 1/20 0.36
HTR1B P28222 1/20 0.36
LIPG Q9Y5X9 1/20 0.35
MEN1 O00255 1/20 0.34
TP53 P04637 1/20 0.34
CYP3A4 P08684 1/20 0.34
ALOX5 P09917 1/20 0.34
MAPT P10636 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
BID P55957 3/20 0.33
MCL1 Q07820 3/20 0.33
BCL2L1 Q07817 2/20 0.33
BAK1 Q16611 2/20 0.33
KAT8 Q9H7Z6 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27976370 0.98 TYR (0.40) TYRHTR1AHTR1DHTR1BLIPG
SCHEMBL11041473 0.94 HTR1A (0.35) TYRHTR1AHTR1DHTR1BLIPG
SCHEMBL27976364 0.94 HTT (0.35) TYRHTR1AHTR1DHTR1BMAPT
SCHEMBL11041595 0.82 TYMP (0.34) TP53CYP3A4ALOX5TYMPGPR84
SCHEMBL30294022 0.80 TYR (0.41) TYRHTR1AHTR1DHTR1BLIPG
SCHEMBL10755010 0.78 LIPG (0.38) TYRHTR1AHTR1DHTR1BLIPG
Hydrochloric Acid SCHEMBL28555353 0.78 TYR (0.40) TYRHTR1AHTR1DHTR1BLIPG
SCHEMBL9679897 0.76 MAPT (0.39) TYRHTR1AHTR1DHTR1BLIPG
SCHEMBL9015242 0.74 MAPT (0.38) HTR1AHTR1DHTR1BLIPGMAPT
SCHEMBL9287050 0.73 GPR84 (0.34) TYRTP53CYP3A4TYMPGPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005024058-A2 COMPOUNDS FOR THE TREATMENT OF DISEASES INVOLVING COGNITIVE IMPAIRMENT, SUCH AS ALZHEIMER’S DISEASE, AND METHODS FOR IDENTIFYING SUCH COMPOUNDS GALAPAGOS N.V. (BE) 2005-03-17 WO claimed
CN-116348105-A Pharmaceutically acceptable salts of arylpyrrole derivatives 圣提内尔肿瘤学有限公司 2023-06-27 CN disclosed
CN-114585605-A Pharmaceutical compounds 圣提内尔肿瘤学有限公司 2022-06-03 CN disclosed
EP-1431293-B1 WATER-SOLUBLE PHENYLPYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME KOWA CO (JP) 2011-06-08 EP disclosed
US-20090270399-A1 NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS KOWA CO., LTD. (JP) 2009-10-29 US disclosed
EP-1043317-B1 PYRIDAZINE DERIVATIVES AND MEDICAMENTS CONTAINING THEM AS ACTIVE INGREDIENT KOWA CO (JP) 2009-04-15 EP disclosed
US-20090069332-A1 NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS KOWA CO., LTD. (JP) 2009-03-12 US disclosed
EP-2017266-A1 Pyridazine derivatives and medicines containing the same as effective ingredients Kowa Co., Ltd. (JP) 2009-01-21 EP disclosed
US-20080119474-A1 NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS KOWA CO., LTD. (JP) 2008-05-22 US disclosed
US-20070208025-A1 NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS KOWA CO., LTD. (JP) 2007-09-06 US disclosed
EP-1196167-A1 METHOD OF REDUCING NEURONAL INJURY OR APOPTOSIS Lipton, Stuart A. (US) 2002-04-17 EP disclosed
US-6348468-B1 THESE COMPOUNDS HAVE EXCELLENT INHIBITORY ACTIVITY AGAINST INTERLEUKIN-1.BETA. PRODUCTION, IMMUNE SYSTEM DISEASES, INFLAMMATORY DISEASES, ISCHEMIC DISEASES AND THE LIKE. KOWA CO., LTD. (JP) 2002-02-19 US disclosed
EP-1178981-A1 SUBSTITUTED 3-PYRIDYL-4-ARYLPYRROLES, AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS Ortho-Mcneil Pharmaceutical, Inc. (US) 2002-02-13 EP disclosed
EP-1156039-A1 PYRIDAZIN-3-ONE DERIVATIVES AND MEDICINES CONTAINING THE SAME Kowa Co., Ltd. (JP) 2001-11-21 EP disclosed
WO-2001001986-A1 METHOD OF REDUCING NEURONAL INJURY OR APOPTOSIS LIPTON STUART A (US) 2001-01-11 WO disclosed
EP-1061077-A1 NOVEL PYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT Kowa Co., Ltd. (JP) 2000-12-20 EP disclosed
WO-2000069847-A1 SUBSTITUTED 3-PYRIDYL-4-ARYLPYRROLES, AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2000-11-23 WO disclosed
EP-1043317-A1 NOVEL PYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT Kowa Co., Ltd. (JP) 2000-10-11 EP disclosed
US-5387693-A Intermediates for inhibitors of cholesterol biosynthesis ORTHO PHARMACEUTICAL CORPORATION (US) 1995-02-07 US disclosed
US-5134155-A Anticholesterol ORTHO PHARMACEUTICAL CORPORATION (US) 1992-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208025-A1 NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS IL1B, IL1R1, TLR1 TYR 1256/4885HTR1A 1114/4885HTR1D 1835/4885
US-20090270399-A1 NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS IL1B, IL1R1, TLR1 TYR 1308/4885HTR1A 974/4885HTR1D 1630/4885
US-20090069332-A1 NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS IL1B, IL1R1, TLR1 TYR 1308/4885HTR1A 974/4885HTR1D 1630/4885
US-20080119474-A1 NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS IL1B, IL1R1, TLR1 TYR 1256/4885HTR1A 1114/4885HTR1D 1835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.